Asia Regenerative Medicine secures Series A funding to boost kidney cell and device pipeline

Asia Regenerative Medicine, a company specializing in cell therapy and bio-artificial organ research and development, recently announced the successful completion of its Series A funding round. The proceeds will be primarily allocated to the clinical application and trials for iNPC101, a human renal progenitor cell injection derived from iPSCs, the registration and clinical study of the AK00 hemofiltration enhancement device, as well as daily operations and team expansion.

Asia Regenerative Medicine is deeply committed to developing innovative therapies for kidney diseases, leveraging two core technology platforms: stem cell culture/differentiation and biomaterials for regeneration. The company has established a diversified pipeline encompassing cell therapies, innovative medical devices, and bio-artificial organs. This funding round will accelerate the clinical advancement of its product portfolio.

Ms. Liu Yihua, Founding Partner of the lead investor, Dongna Investment (东纳投资), stated: "We firmly believe regenerative medicine represents the next-generation core technology that will transform traditional disease treatment paradigms. Within the field of cell-based pharmaceuticals, iPSC-based product development is among the most challenging endeavors, yet its therapeutic potential in areas with limited treatment options is highly promising. Among the various application pathways for iPSC technology, the Huayuan team has focused on the kidney—an area with a large patient population and significant unmet clinical needs—and achieved groundbreaking technological advancements globally. They have not only successfully established efficient and stable differentiation of iPSCs into functional renal progenitor cells but have also built a comprehensive R&D pipeline spanning from cell therapy to bio-artificial organs."

"The iNPC101 injection holds the potential to fundamentally repair damaged kidney tissues, transforming the current treatment paradigm for kidney disease from 'slowing progression without cure' to one of genuine restoration. We hope this product, or the series it represents, can pause the advancement of kidney disease and renal failure, thereby alleviating or reducing patient suffering to a significant degree. This pursuit embodies the long-term value we seek through our investments—to back platform technologies that define the future and support innovations in therapeutic areas with severe unmet medical needs. While this path is undoubtedly challenging and often solitary, we are committed to doing what is difficult yet right. This shared conviction is the very foundation of the partnership between Dongna Investment and Huayuan."

Mr. Zheng Lixin, Founder of the company, stated: "This financing round marks a significant milestone in Huayuan's development. This year, we have submitted an Orphan Drug Designation (ODD) application to the FDA and a Pre-IND application to the CDE. We will vigorously advance the clinical trials for our iPSC-based and medical device products, while simultaneously progressing the preclinical research on renal exosomes and bio-artificial kidney pipelines. Our goal is to provide more effective and safer treatment options for the hundreds of millions of kidney disease patients worldwide."

The global prevalence and number of kidney disease patients continue to rise (over 100 million patients in China alone), and traditional treatments face limitations. This creates a vast market opportunity for Cell and Gene Therapies (CGT) and organ regeneration technologies. With the completion of successive funding rounds, the resources and capital from our investors provide crucial momentum for Huayuan's clinical research and industrialization efforts, driving us closer to our long-term vision of establishing a "regenerative organ factory."